About2020-10-29T04:54:34+00:00
Chimeric Therapeutics Limited

Chimeric Therapeutics is developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.

Science Translation Medicine